All In Biotech

Drug Trial Radar · NCT04912869

A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).

A Phase IB Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Patients With Sickle Cell Disease (SCD)

Last checked: Nov 20, 2026Latest source record: Aug 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Mar 26, 2022

Primary completion

Dec 23, 2024

Study completion Aug 15, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate crovalimab for the treatment of a sickle cell pain crisis (also known as a VOE) that requires hospitalisation in adult and adolescent participants with SCD. The primary objective of this study is safety and will additionally evaluate pharmacokinetics (how crovalimab is processed by your body), pharmacodynamics (how your body reacts to crovalimab) and the preliminary efficacy of crovalimab compared with placebo.

Conditions

  • Sickle Cell Disease

Interventions

  • CrovalimabDrug

    Crovalimab will be administered as a single dose of 1000 milligrams (mg) IV (for participants with a body weight between 40 kilograms (kg) and 100 kg) or 1500 mg IV (for participants with a body weight \>=100 kg).

  • PlaceboDrug

    Placebo will be administered as a single IV infusion, with an equal volume and over the same duration as weight- based crovalimab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Adverse Events (AEs)Time frame: Baseline up to Day 84
  2. Percentage of Participants with Infusion-Related Reactions and HypersensitivityTime frame: Baseline up to Day 84

Locations

16 sites in 10 countries. Site status is shown where the registry gives one.

  • Children'S Healthcare of Atlanta

    Atlanta, Georgia

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Hospital Sao Rafael - HSR

    Salvador, Estado de Bahia, Brazil

  • Hospital das Clinicas - UFRGS

    Porto Alegre, Rio Grande do Sul, Brazil

  • CHU Henri Mondor

    Créteil, France

  • Azienda Ospedaliera di Verona-Policlinico G.B. Rossi

    Verona, Veneto, Italy

  • International Cancer Institute (ICI)

    Eldoret, Kenya

  • Gertrude's Children Hospital

    Nairobi, Kenya

  • American University of Beirut - Medical Center

    Beirut, Lebanon

  • Hopital Nini

    Tripoli, Lebanon

  • Amsterdam UMC Location VUMC

    Amsterdam, Netherlands

  • Charlotte Maxeke Johannesburg Hospital

    Johannesburg, South Africa

  • Hospital General Univ. Gregorio Maranon

    Madrid, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Hospital Universitario Miguel Servet

    Zaragoza, Spain

  • Hammersmith Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.